{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:32:20Z","timestamp":1790764340101,"version":"4.1.0"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T00:00:00Z","timestamp":1112140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate the safety, tolerability and pharmacokinetics of DP\u2010b99 in healthy volunteers. DP\u2010b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2\u2010bis(2\u2010aminophenoxy)ethane\u2010N,N,N\u2032,N\u2032\u2010tetraacetic acid), which selectively modulates the distribution of metal ions in hydrophobic milieu, and is in clinical development as a neuroprotectant for cerebral ischaemic stroke. To our knowledge no BAPTA derivative has ever been administered to man. Here we report the first human administration of DP\u2010b99 in a phase I, two\u2010part, double\u2010blind, randomized placebo controlled study, with single IV doses of 0.003\u20131.0\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003day<jats:sup>\u22121<\/jats:sup> DP\u2010b99 (part 1) or multiple ascending doses of 0.03\u20131.0\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>\u2003day<jats:sup>\u22121<\/jats:sup> DP\u2010b99 over 4\u2003days (part 2).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A double\u2010blind, dose escalating tolerability study of DP\u2010b99 in normal (young \u2013 aged between 18 and 40\u2003years and elderly \u2013 aged between 65 and 85\u2003years) healthy adult male volunteers was conducted. Part 1 of the study investigated single administration of ascending intravenous doses, and part 2 examined the effects of ascending doses given repeatedly over 4\u2003days<jats:italic>.<\/jats:italic> Twenty\u2010four young volunteers in part 1 received single dose administrations and 26 young volunteers in part 2 received repeated ascending dose administrations of either intravenous DP\u2010b99 or placebo. Subsequently, 10\u2003elderly volunteers received repeated intravenous DP\u2010b99 (1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>) or placebo in part 2 over 4\u2003days. Adverse events were identified by either subject self reporting or based upon laboratory parameters (blood chemistry, complete blood cell count, prothrombin time (PT), activated partial thromboplastin (PTT), physical examination, vital signs (blood pressure, pulse rate, respiratory rate, body temperature) and urinalysis. A comprehensive set of cardiovascular parameters was assessed as well (blood pressure, 12 lead\u2010ECG recordings and continuous bedside cardiac monitoring for 6\u2003h on day 1).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The administration of DP\u2010b99 up to the highest dose of 1.0\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> was well tolerated and had an acceptable safety profile up to the highest dose of 1.0\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> tested in both study parts. No serious or severe adverse events were encountered. Eight mild to moderate adverse events were observed in six of the seven young subjects treated with four repeated doses of 1.0\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup>, with reversible phlebitis being the most frequently reported adverse event. The drug was tolerated better at the injection site by the elderly group compared with the younger subjects. No adverse effects were observed in cardiovascular parameters sensitive to trans\u2010membranous calcium concentrations. The pharmacokinetic parameters were derived by noncompartmental analysis. On day 1 following administration of 1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> the mean half\u2010life of DP\u2010b99 in young volunteers was 3.47\u2003\u00b1\u20030.90\u2003h and in the elderly was 2.11\u2003\u00b1\u20030.09\u2003h. On day 4 following the same administration of DP\u2010b99 the mean half\u2010life was 4.36\u2003\u00b1\u20031.49 and 2.10\u2003\u00b1\u20031.14\u2003h in the young and elderly, respectively. There was higher systemic exposure in the elderly, for example <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>, had a mean 1.6\u2010fold higher exposure on day 1 (95% CI Lower 0.90, Upper 2.74) and 2.5\u2010fold on day 4 (95%CI 1.70, 3.68). This increase is in line with the presumed central role of hepatic blood flow in the elimination of DP\u2010b99. No accumulation was observed after repeated dosing with 1\u2003mg\u2003kg<jats:sup>\u22121<\/jats:sup> (mean accumulation calculated by AUC(0, 24\u2003h) (day 4)\u2003:\u2003AUC(0, 24\u2003h) (day 1) and was observed to be between 0.9 and 1.3 (young, elderly).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study suggests that DP\u2010b99 is well tolerated in healthy young and elderly volunteers within the dose range evaluated. Studies to investigate further the efficacy of the compound are in progress.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02378.x","type":"journal-article","created":{"date-parts":[[2005,6,20]],"date-time":"2005-06-20T12:38:34Z","timestamp":1119271114000},"page":"7-16","source":"Crossref","is-referenced-by-count":18,"title":["Clinical pharmacology of DP\u2010b99 in healthy volunteers: First administration to humans"],"prefix":"10.1111","volume":"60","author":[{"given":"Gilad","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzchak","family":"Angel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,3,30]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"American Heart Association (AHA).Heart Disease and Stroke Statistics 2003 Update. Dallas Texas AHA 2004."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000025518.34157.51"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00513-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.neuro.21.1.347"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)01541-8"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00552a018"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1994.122"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.17-10-03538.1997"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(93)90180-Y"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CEMN.0000005320.06215.80"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10083"},{"key":"e_1_2_5_13_2","first-page":"20","article-title":"DP\u2010b99, a neuroprotective agent for cerebral ischemia","volume":"12","author":"Angel I","year":"2000","journal-title":"Bio Tech Int"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-012285751-5\/50053-3"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1983.03340040046030"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(02)01450-4"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199507010-00002"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000047852.05842.3C"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.30.2.338"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02378.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02378.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:15:50Z","timestamp":1697393750000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02378.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,30]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02378.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02378.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,30]]}}}